Who owns Elevation Oncology Inc?
- Ticker: ELEV
- CUSIP Number: 28623u101
Tip: Access positions for across all investors
Analyze quarterly positions in Elevation Oncology with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Elevation Oncology stock
Who bought or sold Elevation Oncology Inc this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| Farallon Capital Management | 3.9M | $20M | 100% | Mar 2024 |
|
| Point72 Asset Management | 3.4M | $17M | 100% | Mar 2024 |
|
| Tang Capital Management | 3.1M | $16M | -17% | Mar 2024 |
|
| Balyasny Asset Management | 3.1M | $16M | 100% | Mar 2024 |
|
| Aisling Capital Management | 2.8M | $1.5M | 0% | Dec 2023 |
|
| venBio Partners | 2.7M | $14M | -7% | Mar 2024 |
|
| Braidwell | 2.4M | $12M | 100% | Mar 2024 |
|
| Qiming U.S. Ventures Management | 2.4M | $1.3M | 0% | Dec 2023 |
|
| Darwin Global Management | 2.3M | $12M | 100% | Mar 2024 |
|
| BVF | 2.3M | $12M | 0% | Mar 2024 |
|
| Citadel Advisors | 1.6M | $8.1M | 165% | Mar 2024 |
|
| Vanguard Group | 1.5M | $7.9M | 31% | Mar 2024 |
|
| Artal Group | 1.5M | $7.8M | 100% | Mar 2024 |
|
| Hudson Bay Capital Management | 1.5M | $7.8M | 177% | Mar 2024 |
|
| Palo Alto Investors | 1.3M | $6.9M | 100% | Mar 2024 |
|
| Logos Global Management | 1.0M | $5.1M | 100% | Mar 2024 |
|
| OrbiMed Advisors | 941k | $4.8M | -37% | Mar 2024 |
|
| Laurion Capital Management | 889k | $4.6M | 100% | Mar 2024 |
|
| Walleye Trading Advisors | 787k | $4.0M | 100% | Mar 2024 |
|
| Millennium Management | 669k | $3.4M | -78% | Mar 2024 |
|
| Goldman Sachs Group | 551k | $2.8M | 100% | Mar 2024 |
|
| Velan Capital Investment Management | 497k | $2.6M | 0% | Mar 2024 |
|
| Sphera Funds Management | 430k | $2.2M | -52% | Mar 2024 |
|
| Exome Asset Management | 369k | $1.9M | 100% | Mar 2024 |
|
| Geode Capital Management | 348k | $1.8M | 51% | Mar 2024 |
|
| Bank of America Corporation | 245k | $1.3M | 59% | Mar 2024 |
|
| Schonfeld Strategic Advisors | 176k | $905k | 1151% | Mar 2024 |
|
| BlackRock | 172k | $882k | 359% | Mar 2024 |
|
| Ikarian Capital | 148k | $760k | -87% | Mar 2024 |
|
| Qube Research & Technologies | 143k | $732k | 100% | Mar 2024 |
|
| Jpmorgan Chase & Co | 137k | $704k | 56833% | Mar 2024 |
|
| Hrt Financial | 133k | $683k | 100% | Mar 2024 |
|
| Marshall Wace | 133k | $681k | 100% | Mar 2024 |
|
| UBS Group | 123k | $629k | -5% | Mar 2024 |
|
| Man Group | 121k | $622k | 100% | Mar 2024 |
|
| Citigroup | 120k | $613k | 100% | Mar 2024 |
|
| Bridgeway Capital Management | 107k | $546k | 88% | Mar 2024 |
|
| Springbok Capital Management | 100k | $515k | 100% | Mar 2024 |
|
| Jane Street | 79k | $405k | 100% | Mar 2024 |
|
| Squarepoint Ops | 69k | $356k | 100% | Mar 2024 |
|
| Dimensional Fund Advisors | 68k | $351k | 100% | Mar 2024 |
|
| Northern Trust | 65k | $332k | 46% | Mar 2024 |
|
| Polar Securities | 55k | $281k | 100% | Mar 2024 |
|
| Annandale Capital | 50k | $27k | 0% | Dec 2023 |
|
| Boothbay Fund Management | 39k | $202k | -85% | Mar 2024 |
|
| American Century Companies | 32k | $162k | 100% | Mar 2024 |
|
| Brevan Howard Capital Management | 28k | $146k | 100% | Mar 2024 |
|
| Morgan Stanley | 28k | $144k | 719% | Mar 2024 |
|
| Bank Of Montreal | 23k | $116k | 100% | Mar 2024 |
|
| Y-Intercept | 22k | $112k | 100% | Mar 2024 |
|
| Ameriprise Financial | 20k | $104k | 100% | Mar 2024 |
|
| Leucadia National Corporation | 18k | $94k | 100% | Mar 2024 |
|
| Palumbo Wealth Management | 18k | $91k | 100% | Mar 2024 |
|
| Cambridge Investment Research Advisors | 16k | $83k | 100% | Mar 2024 |
|
| SG Americas Securities | 12k | $63k | 100% | Mar 2024 |
|
| CTC Alternative Strategies | 11k | $57k | 100% | Mar 2024 |
|
| ADAR1 Capital Management | 8.6k | $44k | 100% | Mar 2024 |
|
| Advisor Group Holdings | 3.0k | $15k | 50% | Mar 2024 |
|
| Wells Fargo & Company | 245.00 | $1.3k | 2% | Mar 2024 |
|
| Tower Research Capital | 23.00 | $117.999200 | -100% | Mar 2024 |
|
Who sold out of Elevation Oncology?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| ExodusPoint Capital Management | Sep 2023 | 1000k | $662k |
| Armistice Capital | Sep 2023 | 750k | $497k |
| DAFNA Capital Management | Dec 2023 | 450k | $242k |
| Two Sigma Investments | Dec 2023 | 365k | $196k |
| Two Sigma Advisers | Dec 2023 | 103k | $55k |
| Royal Bank of Canada | Dec 2023 | 370.00 | $0 |